vs
Martin Marietta Materials（MLM）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Martin Marietta Materials的季度营收约是Revvity的1.5倍（$1.1B vs $772.1M），Martin Marietta Materials净利率更高（24.5% vs 12.7%，领先11.7%），Revvity同比增速更快（5.9% vs -30.1%），Martin Marietta Materials自由现金流更多（$424.0M vs $161.8M），过去两年Revvity的营收复合增速更高（9.0% vs -4.5%）
马丁·玛丽埃塔材料公司是美国大型集料及重型建筑材料供应商，业务覆盖美国26个州、加拿大及加勒比地区，主要为道路、人行道、地基等各类基建项目提供所需原材料。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
MLM vs RVTY — 直观对比
营收规模更大
MLM
是对方的1.5倍
$772.1M
营收增速更快
RVTY
高出36.0%
-30.1%
净利率更高
MLM
高出11.7%
12.7%
自由现金流更多
MLM
多$262.2M
$161.8M
两年增速更快
RVTY
近两年复合增速
-4.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $772.1M |
| 净利润 | $279.0M | $98.4M |
| 毛利率 | 35.0% | — |
| 营业利润率 | 24.6% | 14.5% |
| 净利率 | 24.5% | 12.7% |
| 营收同比 | -30.1% | 5.9% |
| 净利润同比 | -4.8% | 3.9% |
| 每股收益（稀释后） | $4.59 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLMRVTY
| Q4 25 | $1.1B | $772.1M | ||
| Q3 25 | $1.8B | $698.9M | ||
| Q2 25 | $1.8B | $720.3M | ||
| Q1 25 | $1.4B | $664.8M | ||
| Q4 24 | $1.6B | $729.4M | ||
| Q3 24 | $1.9B | $684.0M | ||
| Q2 24 | $1.8B | $691.7M | ||
| Q1 24 | $1.3B | $649.9M |
净利润MLMRVTY
| Q4 25 | $279.0M | $98.4M | ||
| Q3 25 | $414.0M | $46.7M | ||
| Q2 25 | $328.0M | $53.9M | ||
| Q1 25 | $116.0M | $42.2M | ||
| Q4 24 | $293.0M | $94.6M | ||
| Q3 24 | $363.0M | $94.4M | ||
| Q2 24 | $294.0M | $55.4M | ||
| Q1 24 | $1.0B | $26.0M |
毛利率MLMRVTY
| Q4 25 | 35.0% | — | ||
| Q3 25 | 33.1% | 53.6% | ||
| Q2 25 | 30.0% | 54.5% | ||
| Q1 25 | 24.8% | 56.5% | ||
| Q4 24 | 30.0% | — | ||
| Q3 24 | 31.7% | 56.3% | ||
| Q2 24 | 29.3% | 55.7% | ||
| Q1 24 | 21.7% | 54.6% |
营业利润率MLMRVTY
| Q4 25 | 24.6% | 14.5% | ||
| Q3 25 | 27.4% | 11.7% | ||
| Q2 25 | 25.3% | 12.6% | ||
| Q1 25 | 14.3% | 10.9% | ||
| Q4 24 | 24.4% | 16.3% | ||
| Q3 24 | 25.9% | 14.3% | ||
| Q2 24 | 22.6% | 12.4% | ||
| Q1 24 | — | 6.8% |
净利率MLMRVTY
| Q4 25 | 24.5% | 12.7% | ||
| Q3 25 | 22.4% | 6.7% | ||
| Q2 25 | 18.1% | 7.5% | ||
| Q1 25 | 8.6% | 6.4% | ||
| Q4 24 | 18.0% | 13.0% | ||
| Q3 24 | 19.2% | 13.8% | ||
| Q2 24 | 16.7% | 8.0% | ||
| Q1 24 | 83.5% | 4.0% |
每股收益（稀释后）MLMRVTY
| Q4 25 | $4.59 | $0.86 | ||
| Q3 25 | $6.85 | $0.40 | ||
| Q2 25 | $5.43 | $0.46 | ||
| Q1 25 | $1.90 | $0.35 | ||
| Q4 24 | $4.87 | $0.77 | ||
| Q3 24 | $5.91 | $0.77 | ||
| Q2 24 | $4.76 | $0.45 | ||
| Q1 24 | $16.87 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $67.0M | $919.9M |
| 总债务越低越好 | $5.3B | — |
| 股东权益账面价值 | $10.0B | $7.3B |
| 总资产 | $18.7B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.53× | — |
8季度趋势，按日历期对齐
现金及短期投资MLMRVTY
| Q4 25 | $67.0M | $919.9M | ||
| Q3 25 | $57.0M | $931.4M | ||
| Q2 25 | $225.0M | $991.8M | ||
| Q1 25 | $101.0M | $1.1B | ||
| Q4 24 | $670.0M | $1.2B | ||
| Q3 24 | $52.0M | $1.2B | ||
| Q2 24 | $109.0M | $2.0B | ||
| Q1 24 | $2.6B | $1.7B |
总债务MLMRVTY
| Q4 25 | $5.3B | — | ||
| Q3 25 | $5.5B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $5.4B | — | ||
| Q3 24 | $4.0B | — | ||
| Q2 24 | $4.3B | — | ||
| Q1 24 | $4.3B | — |
股东权益MLMRVTY
| Q4 25 | $10.0B | $7.3B | ||
| Q3 25 | $9.7B | $7.4B | ||
| Q2 25 | $9.4B | $7.6B | ||
| Q1 25 | $9.1B | $7.6B | ||
| Q4 24 | $9.5B | $7.7B | ||
| Q3 24 | $9.2B | $7.9B | ||
| Q2 24 | $8.8B | $7.9B | ||
| Q1 24 | $8.9B | $7.8B |
总资产MLMRVTY
| Q4 25 | $18.7B | $12.2B | ||
| Q3 25 | $18.7B | $12.1B | ||
| Q2 25 | $18.1B | $12.4B | ||
| Q1 25 | $17.7B | $12.4B | ||
| Q4 24 | $18.2B | $12.4B | ||
| Q3 24 | $16.5B | $12.8B | ||
| Q2 24 | $16.3B | $13.4B | ||
| Q1 24 | $16.2B | $13.4B |
负债/权益比MLMRVTY
| Q4 25 | 0.53× | — | ||
| Q3 25 | 0.57× | — | ||
| Q2 25 | 0.58× | — | ||
| Q1 25 | 0.60× | — | ||
| Q4 24 | 0.57× | — | ||
| Q3 24 | 0.44× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | 0.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $629.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $424.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 37.2% | 21.0% |
| 资本支出强度资本支出/营收 | 18.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 2.25× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $978.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流MLMRVTY
| Q4 25 | $629.0M | $182.0M | ||
| Q3 25 | $551.0M | $138.5M | ||
| Q2 25 | $387.0M | $134.3M | ||
| Q1 25 | $218.0M | $128.2M | ||
| Q4 24 | $686.0M | $174.2M | ||
| Q3 24 | $600.0M | $147.9M | ||
| Q2 24 | $1.0M | $158.6M | ||
| Q1 24 | $172.0M | $147.6M |
自由现金流MLMRVTY
| Q4 25 | $424.0M | $161.8M | ||
| Q3 25 | $361.0M | $120.0M | ||
| Q2 25 | $208.0M | $115.5M | ||
| Q1 25 | $-15.0M | $112.2M | ||
| Q4 24 | $453.0M | $149.8M | ||
| Q3 24 | $317.0M | $125.6M | ||
| Q2 24 | $-138.0M | $136.6M | ||
| Q1 24 | $-28.0M | $129.7M |
自由现金流率MLMRVTY
| Q4 25 | 37.2% | 21.0% | ||
| Q3 25 | 19.6% | 17.2% | ||
| Q2 25 | 11.5% | 16.0% | ||
| Q1 25 | -1.1% | 16.9% | ||
| Q4 24 | 27.8% | 20.5% | ||
| Q3 24 | 16.8% | 18.4% | ||
| Q2 24 | -7.8% | 19.7% | ||
| Q1 24 | -2.2% | 20.0% |
资本支出强度MLMRVTY
| Q4 25 | 18.0% | 2.6% | ||
| Q3 25 | 10.3% | 2.6% | ||
| Q2 25 | 9.9% | 2.6% | ||
| Q1 25 | 17.2% | 2.4% | ||
| Q4 24 | 14.3% | 3.4% | ||
| Q3 24 | 15.0% | 3.3% | ||
| Q2 24 | 7.9% | 3.2% | ||
| Q1 24 | 16.0% | 2.7% |
现金转化率MLMRVTY
| Q4 25 | 2.25× | 1.85× | ||
| Q3 25 | 1.33× | 2.97× | ||
| Q2 25 | 1.18× | 2.49× | ||
| Q1 25 | 1.88× | 3.03× | ||
| Q4 24 | 2.34× | 1.84× | ||
| Q3 24 | 1.65× | 1.57× | ||
| Q2 24 | 0.00× | 2.87× | ||
| Q1 24 | 0.16× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLM
| Building Materials Business East Group | $774.0M | 68% |
| Building Materials Business West Group | $233.0M | 20% |
| Services | $88.0M | 8% |
| Other | $45.0M | 4% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
